{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " # Multi-Step Agentic RAG with Azure AI Services\n",
    " \n",
    " This notebook demonstrates a Multi-Step Agentic RAG (Retrieval Augmented Generation) system that provides a cardiology-focused AI assistant with access to multiple data sources:\n",
    "\n",
    " 1. **Structured Data** (Azure SQL Database) - Patient medical records and information\n",
    " 2. **Unstructured Data** (Azure AI Search) - Medical guidelines from the American College of Cardiology\n",
    " 3. **Web Data** (Azure AI Agent Service with Bing Grounding Tool) - Real-time web information\n",
    " \n",
    " The system uses Azure OpenAI's function/tool calling capabilities to orchestrate the retrieval process and generate comprehensive responses to medical queries."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "!pip install -r requirements.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 1. Import Libraries and Set Up Environment\n",
    " We'll start by importing the necessary libraries and loading environment variables.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {},
   "outputs": [],
   "source": [
    "import os\n",
    "import json\n",
    "import pandas as pd\n",
    "import pyodbc\n",
    "import sqlalchemy\n",
    "from azure.ai.projects import AIProjectClient\n",
    "from azure.ai.projects.models import BingGroundingTool\n",
    "from azure.core.credentials import AzureKeyCredential\n",
    "from azure.identity import DefaultAzureCredential\n",
    "from azure.search.documents import SearchClient\n",
    "from azure.search.documents.models import VectorizableTextQuery\n",
    "from dotenv import load_dotenv\n",
    "from openai import AzureOpenAI\n",
    "from rich.console import Console\n",
    "from rich.panel import Panel\n",
    "\n",
    "load_dotenv()\n",
    "console = Console()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 2. Configure Azure Services\n",
    "\n",
    "Next, we set up all the necessary configurations for the Azure services we'll be using.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "# Azure OpenAI configuration\n",
    "AZURE_OPENAI_API_KEY = os.getenv(\"AZURE_OPENAI_API_KEY\", \"your-azure-openai-api-key\")\n",
    "AZURE_OPENAI_API_VERSION = os.getenv(\"AZURE_OPENAI_API_VERSION\", \"2024-10-21\")\n",
    "AZURE_OPENAI_ENDPOINT = os.getenv(\"AZURE_OPENAI_ENDPOINT\", \"https://your-azure-openai-endpoint.openai.azure.com/\")\n",
    "AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME = os.getenv(\"AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME\", \"gpt-4o\")\n",
    "\n",
    "# Azure AI Search configuration\n",
    "AZURE_SEARCH_ENDPOINT = os.getenv(\"AZURE_SEARCH_SERVICE_ENDPOINT\", \"https://your-search-service.search.windows.net\")\n",
    "AZURE_SEARCH_KEY = os.getenv(\"AZURE_SEARCH_ADMIN_KEY\", \"your-azure-search-key\")\n",
    "SEARCH_INDEX_NAME = \"acc-guidelines-index\"\n",
    "\n",
    "# Azure AI Project configuration for Bing Grounding\n",
    "AZURE_CONNECTION_STRING = os.getenv(\"AZURE_CONNECTION_STRING\", \"your-azure-connection-string\")\n",
    "BING_CONNECTION_NAME = os.getenv(\"BING_CONNECTION_NAME\", \"fsunavalabinggrounding\")\n",
    "\n",
    "# Azure SQL connection details (for patient data)\n",
    "server = os.getenv(\"AZURE_SQL_SERVER_NAME\")\n",
    "database = os.getenv(\"AZURE_SQL_DATABASE_NAME\")\n",
    "username = os.getenv(\"AZURE_SQL_USER_NAME\")\n",
    "password = os.getenv(\"AZURE_SQL_PASSWORD\")\n",
    "driver = '{ODBC Driver 17 for SQL Server}'\n",
    "\n",
    "# Create an Azure SQL connection string\n",
    "AZURE_SQL_CONNECTION_STRING = f\"DRIVER={driver};SERVER={server};DATABASE={database};UID={username};PWD={password}\"\n",
    "\n",
    "# Initialize the Azure OpenAI client\n",
    "openai_client = AzureOpenAI(\n",
    "    api_key=AZURE_OPENAI_API_KEY,\n",
    "    api_version=AZURE_OPENAI_API_VERSION,\n",
    "    azure_endpoint=AZURE_OPENAI_ENDPOINT,\n",
    ")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 3. Define Tool Functions\n",
    "\n",
    "Now we'll implement the three tool functions that our agent will use to access different data sources.\n",
    "\n",
    "### 3.1 Unstructured Data Tool: ACC Guidelines Search via Azure AI Search\n",
    "\n",
    "This tool retrieves relevant American College of Cardiology guidelines using Azure AI Search with semantic and vector search capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_acc_guidelines(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the Azure AI Search index 'acc-guidelines-index' \n",
    "    for relevant American College of Cardiology (ACC) guidelines.\n",
    "    \"\"\"\n",
    "    credential = AzureKeyCredential(AZURE_SEARCH_KEY)\n",
    "    client = SearchClient(\n",
    "        endpoint=AZURE_SEARCH_ENDPOINT,\n",
    "        index_name=SEARCH_INDEX_NAME,\n",
    "        credential=credential,\n",
    "    )\n",
    "    \n",
    "    results = client.search(\n",
    "        search_text=query,\n",
    "        vector_queries=[\n",
    "            VectorizableTextQuery(\n",
    "                text=query,\n",
    "                k_nearest_neighbors=10,   # Adjust as needed\n",
    "                fields=\"embedding\"   # Adjust based on your index schema\n",
    "            )\n",
    "        ],\n",
    "        query_type=\"semantic\",\n",
    "        semantic_configuration_name=\"default\",\n",
    "        search_fields=[\"chunk\"],\n",
    "        top=10,\n",
    "        include_total_count=True\n",
    "    )\n",
    "    \n",
    "    retrieved_texts = []\n",
    "    for result in results:\n",
    "        content_chunk = result.get(\"chunk\", \"\")\n",
    "        retrieved_texts.append(content_chunk)\n",
    "    \n",
    "    context_str = \"\\n\".join(retrieved_texts) if retrieved_texts else \"No relevant guidelines found.\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: ACC Guidelines Search\\nQuery: {query}\",\n",
    "            style=\"bold yellow\"\n",
    "        )\n",
    "    )\n",
    "    return context_str"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ### 3.2 Web Data Tool: Bing Web Grounding via Azure AI Agent Service\n",
    " \n",
    " This tool uses the Azure AI Agent Service with the Bing Web Grounding Tool to search for real-time information from the web. This is a significant improvement over direct Bing Search API calls, as it leverages Azure's AI Agent framework for better context and grounding and remains compliant with Bing's Terms of Use."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [],
   "source": [
    "def search_bing_grounding(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Searches the public web using the Bing Web Grounding Tool via Azure AI Agent Service.\n",
    "    Returns information about recent updates from the web.\n",
    "    \"\"\"\n",
    "    # Create an Azure AI Client\n",
    "    project_client = AIProjectClient.from_connection_string(\n",
    "        credential=DefaultAzureCredential(),\n",
    "        conn_str=AZURE_CONNECTION_STRING,\n",
    "    )\n",
    "    \n",
    "    try:\n",
    "        with project_client:\n",
    "            # Get the Bing connection\n",
    "            bing_connection = project_client.connections.get(\n",
    "                connection_name=BING_CONNECTION_NAME\n",
    "            )\n",
    "            conn_id = bing_connection.id\n",
    "            \n",
    "            # Initialize agent bing tool\n",
    "            bing = BingGroundingTool(connection_id=conn_id)\n",
    "            \n",
    "            # Create agent with the bing tool\n",
    "            agent = project_client.agents.create_agent(\n",
    "                model=\"gpt-4o\", # gpt-4o-mini not supported at this time so we'll use GPT-4o\n",
    "                name=\"bing-search-agent\",\n",
    "                instructions=f\"Search the web for information about: {query}. Provide a concise but comprehensive summary.\",\n",
    "                tools=bing.definitions,\n",
    "                headers={\"x-ms-enable-preview\": \"true\"}\n",
    "            )\n",
    "            \n",
    "            # Create thread for communication\n",
    "            thread = project_client.agents.create_thread()\n",
    "            \n",
    "            # Create message to thread\n",
    "            project_client.agents.create_message(\n",
    "                thread_id=thread.id,\n",
    "                role=\"user\",\n",
    "                content=query,\n",
    "            )\n",
    "            \n",
    "            # Create and process agent run\n",
    "            run = project_client.agents.create_and_process_run(\n",
    "                thread_id=thread.id, \n",
    "                assistant_id=agent.id\n",
    "            )\n",
    "            \n",
    "            if run.status == \"failed\":\n",
    "                result_text = f\"Bing search failed: {run.last_error}\"\n",
    "            else:\n",
    "                # Fetch messages to get the response\n",
    "                messages = project_client.agents.list_messages(thread_id=thread.id)\n",
    "                # Get the last assistant message\n",
    "                assistant_messages = [m for m in messages.get('data', []) if m.get('role') == 'assistant']\n",
    "                if assistant_messages:\n",
    "                    # Extract the text content from the last assistant message\n",
    "                    content_list = assistant_messages[-1].get('content', [])\n",
    "                    result_text = \"\"\n",
    "                    for content_item in content_list:\n",
    "                        if isinstance(content_item, dict) and 'text' in content_item:\n",
    "                            result_text += content_item.get('text', \"\")\n",
    "                    \n",
    "                    if not result_text:\n",
    "                        result_text = \"No results found.\"\n",
    "                else:\n",
    "                    result_text = \"No results found.\"\n",
    "            \n",
    "            # Clean up resources\n",
    "            project_client.agents.delete_agent(agent.id)\n",
    "            \n",
    "    except Exception as e:\n",
    "        result_text = f\"Bing search failed with error: {str(e)}\"\n",
    "    \n",
    "    console.print(\n",
    "        Panel(\n",
    "            f\"Tool Invoked: Bing Grounding Search\\nQuery: {query}\",\n",
    "            style=\"bold magenta\"\n",
    "        )\n",
    "    )\n",
    "    return result_text"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### 3.3 Structured Data Tool: Patient Data Query via Azure SQL\n",
    "\n",
    "This tool queries a SQL database containing patient medical data, transforming natural language questions into SQL queries.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 45,
   "metadata": {},
   "outputs": [],
   "source": [
    "def lookup_patient_data(query: str) -> str:\n",
    "    \"\"\"\n",
    "    Queries the 'PatientMedicalData' table in Azure SQL and returns the results as a string.\n",
    "    'query' should be a valid SQL statement.\n",
    "    This version uses SQLAlchemy to create an engine, which is fully supported by pandas.read_sql.\n",
    "    \"\"\"\n",
    "    try:\n",
    "        # Construct the connection URI for SQLAlchemy\n",
    "        connection_uri = (\n",
    "            f\"mssql+pyodbc://{username}:{password}@{server}/{database}\"\n",
    "            \"?driver=ODBC+Driver+17+for+SQL+Server\"\n",
    "        )\n",
    "        engine = sqlalchemy.create_engine(connection_uri)\n",
    "        \n",
    "        # Use the engine in pandas.read_sql, which avoids the warning\n",
    "        df = pd.read_sql(query, engine)\n",
    "        if df.empty:\n",
    "            return \"No rows found.\"\n",
    "        return df.to_string(index=False)\n",
    "    except Exception as e:\n",
    "        return f\"Database error: {str(e)}\""
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 4. Define Tools for OpenAI Function Calling\n",
    " Now we'll configure these tools to work with OpenAI's function calling feature, which allows the LLM to dynamically select and use these tools during conversation.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "tools = [\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_acc_guidelines\",\n",
    "            \"description\": \"Query the ACC guidelines for official cardiology recommendations. Use keywords related to cardiology conditions, treatments, or guidelines.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Keywords or specific question related to cardiology guidelines.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"search_bing_grounding\",\n",
    "            \"description\": \"Perform a public web search for real-time or external information using Bing Grounding. For example, 'FDA new hyperlipidemia drugs', 'recent hypertension medication approvals'.\",\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"General query to retrieve public data.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    },\n",
    "    {\n",
    "        \"type\": \"function\",\n",
    "        \"function\": {\n",
    "            \"name\": \"lookup_patient_data\",\n",
    "            \"description\": (\n",
    "                \"Query Azure SQL PatientMedicalData table. Schema: \"\n",
    "                \"PatientID: INT (PK, Identity), FirstName: VARCHAR(100), LastName: VARCHAR(100), \"\n",
    "                \"DateOfBirth: DATE, Gender: VARCHAR(20), ContactNumber: VARCHAR(100), EmailAddress: VARCHAR(100), \"\n",
    "                \"Address: VARCHAR(255), City: VARCHAR(100), PostalCode: VARCHAR(20), Country: VARCHAR(100), \"\n",
    "                \"MedicalCondition: VARCHAR(255), Medications: VARCHAR(255), Allergies: VARCHAR(255), BloodType: VARCHAR(10), \"\n",
    "                \"LastVisitDate: DATE, SmokingStatus: VARCHAR(50), AlcoholConsumption: VARCHAR(50), ExerciseFrequency: VARCHAR(50), \"\n",
    "                \"Occupation: VARCHAR(100), Height_cm: DECIMAL(5,2), Weight_kg: DECIMAL(5,2), BloodPressure: VARCHAR(20), \"\n",
    "                \"HeartRate_bpm: INT, Temperature_C: DECIMAL(3,1), Notes: VARCHAR(MAX). Use SQL to retrieve patient data.\"\n",
    "            ),\n",
    "            \"parameters\": {\n",
    "                \"type\": \"object\",\n",
    "                \"properties\": {\n",
    "                    \"query\": {\n",
    "                        \"type\": \"string\",\n",
    "                        \"description\": \"Valid SQL query for PatientMedicalData table to get patient information.\"\n",
    "                    }\n",
    "                },\n",
    "                \"required\": [\"query\"]\n",
    "            }\n",
    "        }\n",
    "    }\n",
    "]\n",
    "\n",
    "# Map the tool names to the actual function implementations\n",
    "tool_implementations = {\n",
    "    \"search_acc_guidelines\": search_acc_guidelines,\n",
    "    \"search_bing_grounding\": search_bing_grounding,\n",
    "    \"lookup_patient_data\": lookup_patient_data,\n",
    "}"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 5. Define System Prompt for the Agent\n",
    "\n",
    "The system prompt sets the context and instructions for the Agent, defining its role and capabilities.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 52,
   "metadata": {},
   "outputs": [],
   "source": [
    "# ----------------------------\n",
    "# System Prompt for the Agent\n",
    "# ----------------------------\n",
    "SYSTEM_PROMPT = (\n",
    "    \"You are a cardiology-focused AI assistant with access to three tools:\\n\"\n",
    "    \"1) 'lookup_patient_data' for querying patient records from Azure SQL.\\n\"\n",
    "    \"2) 'search_acc_guidelines' for official ACC guidelines.\\n\"\n",
    "    \"3) 'search_bing_grounding' for real-time public information.\\n\\n\"\n",
    "    \"You can call these tools in any order, multiple times if needed, to gather all the context.\\n\"\n",
    "    \"Stop calling tools only when you have enough information to provide a final, cohesive answer.\\n\"\n",
    "    \"Then output your final answer to the user.\"\n",
    ")\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## 6. Implement the Multi-Step Agent\n",
    "\n",
    " Now we'll create the agent that orchestrates the entire process. This agent will:\n",
    "\n",
    "1.  Receive a user query\n",
    "2.  Decide which tools to call and in what order\n",
    "3.  Parse the results from each tool\n",
    "4.  Synthesize a comprehensive answer\n",
    "\n",
    "The agent can make multiple calls to different tools before providing a final answer, allowing for complex, multi-step reasoning.\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [],
   "source": [
    "def run_multi_step_agent(user_query: str, max_steps: int = 10):\n",
    "    \"\"\"\n",
    "    A multi-step agent with enhanced debugging logs using the new tools syntax.\n",
    "    \"\"\"\n",
    "    messages = [\n",
    "        {\"role\": \"system\", \"content\": SYSTEM_PROMPT},\n",
    "        {\"role\": \"user\", \"content\": user_query}\n",
    "    ]\n",
    "\n",
    "    for step in range(max_steps):\n",
    "        console.print(Panel(f\"**Step {step+1}**: Starting step {step+1}\", title=\"Step Start\", style=\"bold cyan\"))\n",
    "        \n",
    "        response = openai_client.chat.completions.create(\n",
    "            model=AZURE_OPENAI_CHAT_COMPLETION_DEPLOYED_MODEL_NAME,\n",
    "            messages=messages,\n",
    "            tools=tools,\n",
    "            tool_choice=\"auto\",\n",
    "            max_tokens=8000,\n",
    "        )\n",
    "        response_message = response.choices[0].message\n",
    "        \n",
    "        console.print(Panel(f\"[DEBUG] Step {step+1}: Raw response_message: {response_message}\", title=\"Raw Response\", style=\"dim\"))\n",
    "        \n",
    "        # IMPORTANT: Append the assistant's message (which includes tool_calls) to the conversation.\n",
    "        messages.append(response_message)\n",
    "        \n",
    "        if response_message.tool_calls:\n",
    "            for tool_call in response_message.tool_calls:\n",
    "                function_name = tool_call.function.name\n",
    "                arguments_str = tool_call.function.arguments\n",
    "                \n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool called: {function_name}\", title=\"Tool Call Info\", style=\"bold magenta\"))\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: arguments_str: {arguments_str}\", title=\"Arguments String\", style=\"magenta\"))\n",
    "                \n",
    "                if arguments_str.strip() == \"\":\n",
    "                    function_args = {}\n",
    "                else:\n",
    "                    try:\n",
    "                        function_args = json.loads(arguments_str)\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (JSON parsed): {function_args}\", title=\"Parsed Arguments\", style=\"green\"))\n",
    "                    except json.JSONDecodeError as e:\n",
    "                        function_args = {}\n",
    "                        console.print(\n",
    "                            Panel(\n",
    "                                \"Warning: Could not decode tool call arguments; defaulting to empty dict.\",\n",
    "                                title=\"JSONDecodeError\",\n",
    "                                style=\"bold red\"\n",
    "                            )\n",
    "                        )\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: JSONDecodeError details: {e}\", title=\"JSONDecodeError Detail\", style=\"bold red\"))\n",
    "                        console.print(Panel(f\"[DEBUG] Step {step+1}: function_args (defaulted): {function_args}\", title=\"Defaulted Arguments\", style=\"red\"))\n",
    "                \n",
    "                # Ensure the 'query' key is present\n",
    "                if \"query\" not in function_args or not function_args[\"query\"]:\n",
    "                    function_args[\"query\"] = user_query\n",
    "                    console.print(Panel(f\"[DEBUG] Step {step+1}: 'query' key defaulted to user_query: {user_query}\", title=\"Defaulted Query Key\", style=\"yellow\"))\n",
    "                \n",
    "                console.print(\n",
    "                    Panel(\n",
    "                        f\"**Step {step+1}**: LLM calls tool [bold]{function_name}[/bold]\\n\\n\"\n",
    "                        f\"**Arguments**:\\n{json.dumps(function_args, indent=2)}\",\n",
    "                        title=\"Tool Call\",\n",
    "                        style=\"bold blue\"\n",
    "                    )\n",
    "                )\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Calling tool implementation: {function_name} with args: {function_args}\", title=\"Tool Implementation Call\", style=\"bold magenta\"))\n",
    "                \n",
    "                tool_fn = tool_implementations.get(function_name)\n",
    "                if tool_fn is None:\n",
    "                    tool_output = f\"[Error] No implementation for tool '{function_name}'.\"\n",
    "                else:\n",
    "                    tool_output = tool_fn(**function_args)\n",
    "                console.print(Panel(f\"[DEBUG] Step {step+1}: Tool output: {tool_output}\", title=\"Tool Output\", style=\"italic blue\"))\n",
    "                \n",
    "                # Format the tool response message correctly\n",
    "                messages.append({\n",
    "                    \"tool_call_id\": tool_call.id,\n",
    "                    \"role\": \"tool\",\n",
    "                    \"name\": function_name,\n",
    "                    \"content\": str(tool_output),  # Simple string for tool response\n",
    "                })\n",
    "        else:\n",
    "            final_answer = response_message.content\n",
    "            console.print(\n",
    "                Panel(\n",
    "                    final_answer,\n",
    "                    title=\"Final Answer\",\n",
    "                    style=\"bold green\",\n",
    "                    border_style=\"yellow\"\n",
    "                )\n",
    "            )\n",
    "            return\n",
    "\n",
    "    console.print(\n",
    "        Panel(\n",
    "            \"Max steps reached without a final answer. Stopping.\",\n",
    "            title=\"Warning\",\n",
    "            style=\"bold red\"\n",
    "        )\n",
    "    )\n",
    "    return"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    " ## 7. Execute the Agent with a Sample Query\n",
    " \n",
    " Now let's run the agent with a cardiology-related question to see how it works. The agent will decide which tools to use and in what order to provide the most comprehensive answer."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "user_question_1 = \"What does the ACC recommend as first-line therapy for hypertension in elderly patients?\"\n",
    "run_multi_step_agent(user_question_1)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "user_question_2 = \"Any latest FDA approvals or clinical trial facts related to Ozempic and how it impacts cardiovascular diseases?\"\n",
    "run_multi_step_agent(user_question_2)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": [
    "user_question_3 = \"How many patients have Hypertension and are prescribed Lisinopril?\"\n",
    "# The agent should generate a valid SQL query, for example:\n",
    "## Note, the answer will depend on the actual data in the database (it should return 1071!)\n",
    "run_multi_step_agent(user_question_3)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 1**: Starting step 1                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 1**: Starting step 1\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant',       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ audio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_mGaA5JhApyGSEsbOO6VZfPxo',   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ function=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = \\'Gloria\\' AND       │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ LastName = \\'Paul\\'\"}', name='lookup_patient_data'), type='function'),                                          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_m8Tp8mTWUA2OhxGF9UHiwCnT', function=Function(arguments='{\"query\":        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ \"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'),                                            │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ ChatCompletionMessageToolCall(id='call_HrMIbfeKN3FT0HloW30qKHNQ', function=Function(arguments='{\"query\": \"FDA   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ new hyperlipidemia medications February 2025\"}', name='search_bing_grounding'), type='function')])              │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 1: Raw response_message: ChatCompletionMessage(content=None, refusal=None, role='assistant', \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2maudio=None, function_call=None, tool_calls=[ChatCompletionMessageToolCall(id='call_mGaA5JhApyGSEsbOO6VZfPxo', \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfunction=Function(arguments='{\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = \\'Gloria\\' AND \u001b[0m\u001b[2m     \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mLastName = \\'Paul\\'\"}', name='lookup_patient_data'), type='function'), \u001b[0m\u001b[2m                                        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_m8Tp8mTWUA2OhxGF9UHiwCnT', function=Function(arguments='{\"query\": \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m\"hyperlipidemia\"}', name='search_acc_guidelines'), type='function'), \u001b[0m\u001b[2m                                          \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mChatCompletionMessageToolCall(id='call_HrMIbfeKN3FT0HloW30qKHNQ', function=Function(arguments='{\"query\": \"FDA \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnew hyperlipidemia medications February 2025\"}', name='search_bing_grounding'), type='function')])\u001b[0m\u001b[2m             \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: lookup_patient_data                                                                │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: lookup_patient_data\u001b[0m\u001b[1;35m                                                               \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ LastName = 'Paul'\"}                                                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND \u001b[0m\u001b[35m     \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35mLastName = 'Paul'\"}\u001b[0m\u001b[35m                                                                                            \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE FirstName =      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ 'Gloria' AND LastName = 'Paul'\"}                                                                                │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': \"SELECT * FROM PatientMedicalData WHERE FirstName = \u001b[0m\u001b[32m    \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m'Gloria' AND LastName = 'Paul'\"}\u001b[0m\u001b[32m                                                                               \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool lookup_patient_data                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34mlookup_patient_data\u001b[0m\u001b[1;34m                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"SELECT * FROM PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"\u001b[0m\u001b[1;34m                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM            │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ PatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"}                                           │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: lookup_patient_data with args: {'query': \"SELECT * FROM \u001b[0m\u001b[1;35m          \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mPatientMedicalData WHERE FirstName = 'Gloria' AND LastName = 'Paul'\"}\u001b[0m\u001b[1;35m                                          \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Address        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ SmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HeartRate_bpm  Temperature_C                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Notes                                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│          1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ year parent. Happen energy level anyone position. Few available thought world development.                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output:  PatientID FirstName LastName DateOfBirth Gender ContactNumber        EmailAddress\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAddress        City PostalCode Country MedicalCondition  Medications Allergies BloodType LastVisitDate \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSmokingStatus AlcoholConsumption ExerciseFrequency            Occupation  Height_cm  Weight_kg BloodPressure  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHeartRate_bpm  Temperature_C                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNotes\u001b[0m\u001b[3;34m                                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m         1    Gloria     Paul  1944-07-15  Other  428-674-1336 keymary@example.com 62908 Fuentes \u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCove\\nLewisberg, MN 13491 Buchananton      59963   India   Hyperlipidemia Atorvastatin      None        O+    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2024-03-26  Never Smoker      Light drinker  1-2 times a week Administrator, sports      176.2       77.7   \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m120/79 mmHg             90           37.6 Affect idea turn either see six. Suggest cultural change nice travel \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34myear parent. Happen energy level anyone position. Few available thought world development.\u001b[0m\u001b[3;34m                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_acc_guidelines                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_acc_guidelines\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia\"}                                                      │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"hyperlipidemia\"}\u001b[0m\u001b[35m                                                     \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia'}                                        │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'hyperlipidemia'}\u001b[0m\u001b[32m                                       \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_acc_guidelines                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"hyperlipidemia\"                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_acc_guidelines\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"hyperlipidemia\"\u001b[0m\u001b[1;34m                                                                                    \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia'}       │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_acc_guidelines with args: {'query': 'hyperlipidemia'}\u001b[0m\u001b[1;35m      \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Tool Invoked: ACC Guidelines Search                                                                             │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│ Query: hyperlipidemia                                                                                           │</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mTool Invoked: ACC Guidelines Search\u001b[0m\u001b[1;33m                                                                            \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33mQuery: hyperlipidemia\u001b[0m\u001b[1;33m                                                                                          \u001b[0m\u001b[1;33m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ severity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ stenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Cerebral Ischemia Databank) studies, respectively (258).                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS I                                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Evidence: B)                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ CLASS IIa                                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ atherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259).  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Level of Evidence: B)                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ achieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ among those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (261–264). (Level of Evidence: B)                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reasonable (261,263,265). (Level of Evidence: B)                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI,  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Trial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ involving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (267). In the ARIC study, the relationships between lipid values and incident ischemic.                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ received service or treatment for the specific condition. Detailed information on the identification of chronic │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ conditions is available from the CMS Chronic Conditions Data Warehouse (13).                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Table 1                                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Table 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ years of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ were 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disease also appeared.                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Table 2                                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Table 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ least 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ pressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mellitus and arthritis completing the remaining prevalent combinations (14).                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 73, N O . 2 4 , 2 0 1 9                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e313                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ As discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.).                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4).         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Secondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ addressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ A smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ present. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ suggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ In young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ starting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ identified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ have been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ individuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ One approach to identifying young adults who could benefit from statins or drug combination would be to detect  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ significant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Children and Adolescents                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle therapy, including moderate caloric restriction and regular aerobic physical activity                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-1—S4.4.4.3-4).|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C (S4.4.4.3-1—S4.4.4.3-3,                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference,   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ obesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ children as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ one-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ rates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ patients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 3.2. Lipid-Lowering Drugs                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Among lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ interventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Triglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ support their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ summarized in Table S3 in the Web Supplement.                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 3.2.1. Statin Therapy                                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ low-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%,                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ moderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by &lt;30% (Table 3). Of course, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ greater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ side effects are discussed in Section 5. Common medications that may potentially interact with statins are      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ listed in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ from the ACC LDL-C Manager (S3.2.1-20).                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 3.2.2. Nonstatin Therapies                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Ezetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ incidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30%        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ depending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ are associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ when fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 8 , N O . 2 2 , 2 0 2 1                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Gulati et al. e199                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # N O V E M B E R 3 0 , 2 0 2 1 : e 1 8 7 – e 2 8 5                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2021 Chest Pain Guideline                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Most patients who present to the ED with chest pain are women, particularly among those $65 years of age (8).   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ The ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches)     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ trial demonstrated that women with moderate-to-severe ischemia are more symptomatic than men (9). Women are     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ less likely to have timely and appropriate care (10). This could be explained by the fact that women are more   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ likely to experience prodromal symptoms when they seek medical care (11). Women may also present with           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ accompanying symptoms (e.g., nausea, fatigue, and shortness of breath) more often than men (12-14). However,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ chest pain remains the predominant symptom reported by women among those ultimately diagnosed with ACS,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ occurring with a frequency equal to men (3,5-7,15,16).                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Traditional risk score tools and physician assessments often underestimate risk in women and misclassify     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ them as having nonischemic chest pain (1,2). The PROMISE (Prospective Multicenter Imaging Study for Evaluation  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of Chest Pain) trial looked at sex differences in the presentation, risk factors, demographics, noninvasive     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ test referrals, and results of 10,003 stable outpatients with suspected CAD (1). Women commonly presented with  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ chest pain symptoms similar to men but also had a greater prevalence of other symptoms such as palpitations,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ jaw and neck pain, as well as back pain. Women also had more cardiovascular risk factors, including             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertension (66.6% versus 63.2%; p&lt;0.001), hyperlipidemia (68.9% versus 66.3%; p¼0.004), older age (62.47.9    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ years of age versus 59.08.4 years of age, p&lt;0.001), cerebral or peripheral artery disease (6.2% versus 4.7%;    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ p&lt;0.001), family history of premature CAD (34.6% versus 29.3%; p&lt;0.001), and sedentary lifestyle (53.5% versus  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 43.4%; p&lt;0.001). Physician assessments often misclassify chest pain as nonanginal. The BARI 2D (Bypass          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Angioplasty Revascularization Investigation 2 Diabetes) trial reported that women with diabetes had a higher    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prevalence of angina than their male counterparts, with a lower functional capacity and a lower incidence of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ obstructive CAD (16).                                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. In the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, men and women  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ #55 years of age were equally likely to present with chest pain (defined as pain, pressure, tightness,          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ discomfort; 89.5% versus 87%, respectively). Women were more likely to report associated symptoms than men      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (e.g., epigastric symptoms, palpitations, and pain or discomfort in the jaw, neck, arms, or between the         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ shoulder blades; 61.9% of women versus 54.8% of men; p&lt;0.001) (3). Similar results were found in the YOUNG-MI   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (Myocardial Infarction) registry where young men and women (#50 years of age) were equally likely to present    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with chest pain, although women were more likely to also have other associated symptoms (7). The HERMES (Highly │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Effective Reperfusion Evaluated in Multiple Endovascular Stroke) study used cardiolinguistic machine learning   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ to record patient-reported symptoms and, in those diagnosed with obstructive CAD, there was no sex difference   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ in the occurrence of chest pain (6). In a prospective trial of 1941 patients (39% women) with suspected ACS     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ examining the diagnostic value of high-sensitivity cardiac troponin (cTn), chest pain was reported in 92% of    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ women and 91% of men (5). Additionally, women with acute myocardial infarction (AMI) were more likely to        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ present with “typical” symptoms than men (77% versus 59%; p¼0.007).                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2.1.2. Considerations for Older Patients With Chest Pain                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation for Considerations for Older Patients With Chest                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 73, N O . 24, 2019                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al. e315                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 25, 2019: e 285 - 350                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # T A B L E 9 Normal and Abnormal Lipid Values in Childhood*                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ | |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|---|                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |TC|&amp;lt;170 (&amp;lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Triglycerides (0-9 y)|&amp;lt;75 (&amp;lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Triglycerides (10-19 y)|&amp;lt;90 (&amp;lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |HDL-C|&amp;gt;45 (&amp;gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&amp;lt;40 (&amp;lt;1.0 mmol/L)|                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |LDL-C|&amp;lt;110 (&amp;lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |Non–HDL-C|&amp;lt;120 (&amp;lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Values given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 38.6; for triglycerides, divide by 88.6.                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ *Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Children. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ for LDL-C.                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ †The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles,              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ respectively. Low cutpoints for HDL-C represent approximately the 10th percentile.                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ National Cholesterol Education Program; SI, Système international d’unités (International System of Units); and │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ TC, total cholesterol.                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Hypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13).          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-13—S4.4.4.3-16).                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ history of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ related genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Subclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ beginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ considered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ suggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ severe hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ screening), according to studies outside the United States demonstrating efficacy of this approach              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (S4.4.4.3-37). Screening for severe                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e300 Grundy et al.                                                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ may be indicated.                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ been no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ ≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ those receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ exclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ follow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ genetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ both primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ administered to patients with primary severe hypercholesterolemia.                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ greater in the combined-therapy group, but there was no difference in carotid intima-media thickness between    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ the 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ placebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ showed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ than that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ indicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ characteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve &lt;50%  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ reduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ mmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ LDL-C lowering (S4.2-9).                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ with or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12). │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ However, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ used in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation.        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Nonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 4. PCSK9 inhibitors are promising drugs for treatment of FH                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ prevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 366:321–9.                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ activity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Promot. 2018. 890117118784226.                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.4.4.3. Children and Adolescents                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ carotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Revolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes.           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2009;4:205–14.                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ lifestyle approach. J Clin Lipidol. 2014;8:181–6.                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ cardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.                                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007;   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 116:1032–40.                                                                                                    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Intervention Study in Children (DISC). Pediatrics. 2001;107:256–64.                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ of the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab.                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 2011;96:E1999–2008.                                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled,    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ blinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemia. JAMA Pediatr. 2013;167:708–13.                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ modification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.                              │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ profile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Paediatr. 1992;81:682–5.                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypercholesterolemic children.                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # e318                                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Grundy et al.                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 2018 Cholesterol Clinical Practice Guideline                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 4.5.2. Hypertriglyceridemia                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendations for Hypertriglyceridemia                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Referenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |COR|LOE|RECOMMENDATIONS|                                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |---|---|---|                                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ (obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ nephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ higher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consider a persistently elevated triglyceride level as a factor favoring initiation or intensification of       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ statin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ |IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ especially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ causes of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol,         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ consumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7, │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ S4.5.2-9).|                                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Synopsis                                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Two categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ triglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ elevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ hypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ acute pancreatitis. Therapies should address excesses in both lipoproteins.                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Recommendation-Specific Supportive Text                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ 1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ associated risk factors by nonpharmacological means where possible. This can best be achieved by identification │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ and treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ disorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens,       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ tamoxifen, raloxifene, retinoids,                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # Brottet et al.                                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # JACC Vol. 57, No. 8, 2011                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # ECVD Guideline: Full Text                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # February 22, 2011:e16 –94                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.2. Cessation of Tobacco Smoking                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.2.1. Recommendation for Cessation of Tobacco Smoking                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3. Control of Hyperlipidemia                                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.3.1. Recommendations for Control of Hyperlipidemia                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.4. Management of Diabetes Mellitus                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.4.1. Recommendations for Management of Diabetes Mellitus in Patients With Atherosclerosis of the            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Extracranial Carotid or Vertebral Arteries                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.5. Hyperhomocysteinemia                                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.6. Obesity and the Metabolic Syndrome                                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.7. Physical Inactivity                                                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8. Antithrombotic Therapy                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8.1. Recommendations for Antithrombotic Therapy in Patients With Extracranial Carotid Atherosclerotic       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Disease Not Undergoing Revascularization                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 6.8.2. Nonsteroidal Anti-Inflammatory Drugs                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7. Revascularization                                                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.1. Recommendations for Selection of Patients for Carotid Revascularization                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2. Carotid Endarterectomy                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1. Randomized Trials of Carotid Endarterectomy                                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1.1. CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS                                                       │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.1.2. CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS                                                      │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2. Factors Affecting the Outcome of Carotid Endarterectomy                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.1. TECHNICAL CONSIDERATIONS                                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.2. CASE SELECTION AND OPERATOR EXPERIENCE                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.2.3. DEMOGRAPHIC AND CLINICAL FACTORS                                                                     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.3. Risks Associated With Carotid Endarterectomy                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.4. Carotid Endarterectomy in Patients With Unfavorable Anatomy                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.5. Evolution in the Safety of Carotid Surgery                                                             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.6. Evolution of Medical Therapy                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.2.7. Recommendations for Periprocedural Management of Patients Undergoing Carotid Endarterectomy            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3. Carotid Artery Stenting                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.1. Multicenter Registry Studies                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2. Risks Associated With Carotid Artery Stenting                                                          │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2.1. CARDIOVASCULAR COMPLICATIONS                                                                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.2.2. NEUROLOGICAL COMPLICATIONS                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.3. Prevention of Cerebral Embolism in Patients Undergoing Catheter-Based Carotid Intervention             │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.4. Intravascular Ultrasound Imaging in Conjunction With Catheter-Based Carotid Intervention               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.3.5. Management of Patients Undergoing Endovascular Carotid Artery Stenting                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4. Comparative Assessment of Carotid Endarterectomy and Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.1. Nonrandomized Comparison of Carotid Endarterectomy With Carotid Artery Stenting                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.2. Meta-Analyses Comparing Carotid Endarterectomy and Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3. Randomized Trials Comparing Carotid Endarterectomy and Carotid Artery Stenting                         │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3.1. HIGH-RISK PATIENTS                                                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.3.2. CONVENTIONAL-RISK PATIENTS                                                                           │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.4.4. Selection of Carotid Endarterectomy or Carotid Artery Stenting for Individual Patients With Carotid    │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Stenosis                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5. Durability of Carotid Revascularization                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5.1. Recommendations for Management of Patients Experiencing Restenosis After Carotid Endarterectomy or     │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ Stenting                                                                                                        │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ # 7.5.2. Clinical Durability of Carotid Surgery and Carotid Stenting                                            │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ #                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: than in former smokers, and there was a significant relationship between the \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mseverity of carotid stenosis and pack-years of exposure to tobacco (239). The RRs of finding 60% carotid \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstenosis were 1.5 and 3.9 among cigarette smokers with cerebral ischemia in the NOMASS and the BCID (Berlin \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCerebral Ischemia Databank) studies, respectively (258).\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS I\u001b[0m\u001b[3;34m                                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis to reduce low-density lipoprotein (LDL) cholesterol below 100 mg/dL (111,259,260). (Level of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEvidence: B)\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mCLASS IIa\u001b[0m\u001b[3;34m                                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Treatment with a statin medication is reasonable for all patients with extracranial carotid or vertebral \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34matherosclerosis who sustain ischemic stroke to reduce LDL-cholesterol to a level near or below 70 mg/dL (259). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. If treatment with a statin (including trials of higher-dose statins and higher-potency statins) does not \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34machieve the goal selected for a patient, intensifying LDL-lowering drug therapy with an additional drug from \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mamong those with evidence of improving outcomes (i.e., bile acid sequestrants or niacin) can be effective \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(261–264). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. For patients who do not tolerate statins, LDL-lowering therapy with bile acid sequestrants and/or niacin is \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreasonable (261,263,265). (Level of Evidence: B)\u001b[0m\u001b[3;34m                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe relationship between cholesterol and ischemic stroke is not as evident as that between cholesterol and MI, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand findings from population-based studies are inconsistent. In the MR FIT (Multiple Risk Factor Intervention \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTrial), comprising more than 350,000 men, the RR of death increased progressively with serum cholesterol, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexceeding 2.5 in those with the highest levels (266). An analysis of 45 prospective observational cohorts \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minvolving approximately 450,000 individuals, however, found no association of hypercholesterolemia with stroke \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(267). In the ARIC study, the relationships between lipid values and incident ischemic.\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreceived service or treatment for the specific condition. Detailed information on the identification of chronic\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconditions is available from the CMS Chronic Conditions Data Warehouse (13).\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Table 1\u001b[0m\u001b[3;34m                                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTable 1 shows the 10 most common comorbidities for each index cardiovascular condition for beneficiaries ‡65 \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34myears of age in 2012 (13). The numbers of Medicare beneficiaries with the 4 index cardiovascular conditions \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwere 8,678,060 with ischemic heart disease, 4,366,489 with heart failure, 2,556,839 with atrial fibrillation, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand 1,145,719 with stroke. Two conditions that are major cardiovascular risk factors—hypertension and \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhyperlipidemia—constitute the most frequent dyad. Hypertension, hyperlipidemia, and ischemic heart disease were\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe 3 most prevalent comorbidities for patients with heart failure, atrial fibrillation, and stroke, whereas \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertension, hyperlipidemia, and diabetes mellitus were the most prevalent comorbidities in those with \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mischemic heart disease; however, arthritis, anemia, chronic obstructive pulmonary disease, and Alzheimer’s \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisease also appeared.\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Table 2\u001b[0m\u001b[3;34m                                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTable 2 lists the top 5 most prevalent dyad and triad comorbidities for beneficiaries ‡65 years of age with at \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mleast 2 (for dyads) or 3 (for triads) chronic conditions. Combinations of high cholesterol, high blood \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpressure, and ischemic heart disease were most frequently represented in the dyads and triads, with diabetes \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmellitus and arthritis completing the remaining prevalent combinations (14).\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 73, N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e313\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 25, 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAs discussed in these guidelines (Section 4.2.) FH often goes undiagnosed. Young adults with primary elevations\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof LDL-C ≥ 190 mg/dl have a long-term ASCVD burden (S4.4.4.2-3), and statin therapy is recommended. In adults \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith hypercholesterolemia, cascade screening often identifies other family members with elevated LDL-C (Section\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.).\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, even moderate hypercholesterolemia can accelerate development of atherosclerosis (S4.4.4.2-4). \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSecondary causes of elevated cholesterol—hypothyroidism (TSH), obstructive liver disease (liver panel), renal \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisease and nephrosis (creatinine and urine analysis) as well as dietary and medication history—should be \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34maddressed appropriately (S4.4.4.2-5). Elevations of LDL-C persisting after excluding secondary causes suggests \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetic forms of hypercholesterolemia. Young adults who experience prolonged exposure to hyperlipidemia prior \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto age 55 are shown to have significantly increased risk of coronary heart disease (S4.4.4.2-6). Intensive \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle change has the potential to reduce the hyperlipidemia and associated ASCVD risk factor burden.\u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mA smaller group, but even at higher risk, are young adults with persistent, moderate hypercholesterolemia \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(LDL-C 160-189 mg/dL), especially when risk-enhancing factors, such as a family history of premature ASCVD, are\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpresent. Since there is increased probability of genetic FH in this LDL-C range, clinical judgment would \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuggest that these high risk young adults will benefit from long-term statin therapy (S4.4.4.2-7) (Section \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4.2.). Indeed, it has been shown that those with higher LDL-C can gain as much or more benefit from cholesterol\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction as do those with lower pretreatment LDL-C but at higher risk (S4.4.4.2-8, S4.4.4.2-9).\u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIn young adults without phenotypically severe hypercholesterolemia, risk assessment should begin by estimation \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof lifetime risk (S4.4.4.2-10). The pooled cohort equations (PCE) can be used to estimate lifetime risk \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstarting at age 21 years (see Section 4.4.2.). This information can inform a focused risk discussion designed \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto improve high-risk lifestyle behaviors including tobacco use, sedentary lifestyle and/or poor diet \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.2-11, S4.4.4.2-12). When young adults with hypercholesterolemia or multiple risk factors are \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34midentified, lifestyle intervention is indicated. To date, no long-term RCTs with cholesterol-lowering drugs \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhave been carried out in those 20 to 39 years age. However, a primary prevention RCT in those younger \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindividuals at low to moderate short-term risk, but at high lifetime risk has been proposed (S4.4.4.2-13).\u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mOne approach to identifying young adults who could benefit from statins or drug combination would be to detect \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msignificant coronary atherosclerosis with coronary artery calcium (CAC) scores. Its use for this purpose has \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen suggested (S4.4.4.2-14). But again, absence of RCT data precludes guideline recommendations at this time.\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Children and Adolescents\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 18 to 21.\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|A|In children and adolescents with lipid disorders related to obesity, it is recommended to intensify \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle therapy, including moderate caloric restriction and regular aerobic physical activity \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-1—S4.4.4.3-4).|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In children and adolescents with lipid abnormalities, lifestyle counseling is beneficial for lowering \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C (S4.4.4.3-1—S4.4.4.3-3,\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe diagnosis is made by the presence of any 3 of the following 5 risk factors: elevated waist circumference, \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated serum triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose (Table S2 in\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe Web Supplement). Metabolic syndrome is closely linked to excess weight and particularly to abdominal \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mobesity (S3.1.2-4). Therefore, the prevalence of metabolic syndrome has risen sharply among both adults and \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mchildren as levels of overweight and obesity have risen. Metabolic syndrome is now found in approximately \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mone-third of the adults in the United States (S3.1.2-5) and is likely under-recognized because of insufficient \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrates of screening. The prevalence of metabolic syndrome increases with age and very commonly occurs in \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpatients with type 2 diabetes mellitus. See Table S2 in the Web Supplement.\u001b[0m\u001b[3;34m                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 3.2. Lipid-Lowering Drugs\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAmong lipid-lowering drugs, statins are the cornerstone of therapy, in addition to healthy lifestyle \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34minterventions. Other LDL-lowering drugs include ezetimibe, bile acid sequestrants, and PCSK9 inhibitors. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTriglyceride-lowering drugs are fibrates and niacin; they have a mild LDL-lowering action, but RCTs do not \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msupport their use as add-on drugs to statin therapy (S3.2-1). Characteristics of LDL-lowering drugs are \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msummarized in Table S3 in the Web Supplement.\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 3.2.1. Statin Therapy\u001b[0m\u001b[3;34m                                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe intensity of statin therapy is divided into 3 categories: high-intensity, moderate-intensity, and \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlow-intensity (S3.2.1-1). High-intensity statin therapy typically lowers LDL-C levels by ≥50%, \u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmoderate-intensity statin therapy by 30% to 49%, and low-intensity statin therapy by <30% (Table 3). Of course,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe magnitude of LDL-C lowering will vary in clinical practice (S3.2.1-2). Certain Asian populations may have a\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgreater response to certain statins (S3.2.1-18). Pharmacokinetic profiles among statins are heterogeneous \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Table S4 in the Web Supplement). Statin safety has been extensively evaluated (S3.2.1-19). Statin-associated \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mside effects are discussed in Section 5. Common medications that may potentially interact with statins are \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlisted in Table S5 in the Web Supplement. More information on statin drug–drug interactions can be obtained \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfrom the ACC LDL-C Manager (S3.2.1-20).\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 3.2.2. Nonstatin Therapies\u001b[0m\u001b[3;34m                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEzetimibe is the most commonly used nonstatin agent. It lowers LDL-C levels by 13% to 20% and has a low \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mincidence of side effects (S3.2.2-1, S3.2.2-2). Bile acid sequestrants reduce LDL-C levels by 15% to 30% \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdepending on the dose. Bile acid sequestrants are not absorbed and do not cause systemic side effects, but they\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mare associated with gastrointestinal complaints (e.g., constipation) and can cause severe hypertriglyceridemia \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwhen fasting triglycerides are ≥300 mg/dL (≥3.4 mmol/L). PCSK9 inhibitors are powerful LDL-lowering drugs.\u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 8 , N O . 2 2 , 2 0 2 1\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Gulati et al. e199\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# N O V E M B E R 3 0 , 2 0 2 1 : e 1 8 7 – e 2 8 5\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2021 Chest Pain Guideline\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mMost patients who present to the ED with chest pain are women, particularly among those $65 years of age (8). \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mThe ISCHEMIA (International Study of Comparative Health Effectiveness With Medical and Invasive Approaches) \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtrial demonstrated that women with moderate-to-severe ischemia are more symptomatic than men (9). Women are \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mless likely to have timely and appropriate care (10). This could be explained by the fact that women are more \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlikely to experience prodromal symptoms when they seek medical care (11). Women may also present with \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34maccompanying symptoms (e.g., nausea, fatigue, and shortness of breath) more often than men (12-14). However, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mchest pain remains the predominant symptom reported by women among those ultimately diagnosed with ACS, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34moccurring with a frequency equal to men (3,5-7,15,16).\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Traditional risk score tools and physician assessments often underestimate risk in women and misclassify \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthem as having nonischemic chest pain (1,2). The PROMISE (Prospective Multicenter Imaging Study for Evaluation \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof Chest Pain) trial looked at sex differences in the presentation, risk factors, demographics, noninvasive \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtest referrals, and results of 10,003 stable outpatients with suspected CAD (1). Women commonly presented with \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mchest pain symptoms similar to men but also had a greater prevalence of other symptoms such as palpitations, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mjaw and neck pain, as well as back pain. Women also had more cardiovascular risk factors, including \u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertension (66.6% versus 63.2%; p<0.001), hyperlipidemia (68.9% versus 66.3%; p¼0.004), older age (62.47.9 \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34myears of age versus 59.08.4 years of age, p<0.001), cerebral or peripheral artery disease (6.2% versus 4.7%; \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mp<0.001), family history of premature CAD (34.6% versus 29.3%; p<0.001), and sedentary lifestyle (53.5% versus \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m43.4%; p<0.001). Physician assessments often misclassify chest pain as nonanginal. The BARI 2D (Bypass \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mAngioplasty Revascularization Investigation 2 Diabetes) trial reported that women with diabetes had a higher \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprevalence of angina than their male counterparts, with a lower functional capacity and a lower incidence of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mobstructive CAD (16).\u001b[0m\u001b[3;34m                                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. In the VIRGO (Variation in Recovery: Role of Gender on Outcomes of Young AMI Patients) study, men and women \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m#55 years of age were equally likely to present with chest pain (defined as pain, pressure, tightness, \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdiscomfort; 89.5% versus 87%, respectively). Women were more likely to report associated symptoms than men \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(e.g., epigastric symptoms, palpitations, and pain or discomfort in the jaw, neck, arms, or between the \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mshoulder blades; 61.9% of women versus 54.8% of men; p<0.001) (3). Similar results were found in the YOUNG-MI \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(Myocardial Infarction) registry where young men and women (#50 years of age) were equally likely to present \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith chest pain, although women were more likely to also have other associated symptoms (7). The HERMES (Highly\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mEffective Reperfusion Evaluated in Multiple Endovascular Stroke) study used cardiolinguistic machine learning \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mto record patient-reported symptoms and, in those diagnosed with obstructive CAD, there was no sex difference \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34min the occurrence of chest pain (6). In a prospective trial of 1941 patients (39% women) with suspected ACS \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexamining the diagnostic value of high-sensitivity cardiac troponin (cTn), chest pain was reported in 92% of \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwomen and 91% of men (5). Additionally, women with acute myocardial infarction (AMI) were more likely to \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mpresent with “typical” symptoms than men (77% versus 59%; p¼0.007).\u001b[0m\u001b[3;34m                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2.1.2. Considerations for Older Patients With Chest Pain\u001b[0m\u001b[3;34m                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation for Considerations for Older Patients With Chest\u001b[0m\u001b[3;34m                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 73, N O . 24, 2019\u001b[0m\u001b[3;34m                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al. e315\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 25, 2019: e 285 - 350\u001b[0m\u001b[3;34m                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# T A B L E 9 Normal and Abnormal Lipid Values in Childhood*\u001b[0m\u001b[3;34m                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m| |Acceptable, mg/dL|Borderline, mg/dL|Abnormal, mg/dL|\u001b[0m\u001b[3;34m                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|---|\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|TC|&lt;170 (&lt;4.3 mmol/L)|170-199 (4.3-5.1 mmol/L)|$200 ($5.1 mmol/L)|\u001b[0m\u001b[3;34m                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Triglycerides (0-9 y)|&lt;75 (&lt;0.8 mmol/L)|75-99 (0.8-1.1 mmol/L)|$100 ($1.1 mmol/L)|\u001b[0m\u001b[3;34m                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Triglycerides (10-19 y)|&lt;90 (&lt;1.0 mmol/L)|90-129 (1.0-1.5 mmol/L)|$130 ($1.4 mmol/L)|\u001b[0m\u001b[3;34m                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|HDL-C|&gt;45 (&gt;1.2 mmol/L)|40-45 (1.0-1.2 mmol/L)|&lt;40 (&lt;1.0 mmol/L)|\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|LDL-C|&lt;110 (&lt;2.8 mmol/L)|110-129 (2.8-3.3 mmol/L)|$130 ($3.4 mmol/L)|\u001b[0m\u001b[3;34m                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|Non–HDL-C|&lt;120 (&lt;3.1 mmol/L)|120-144 (3.1-3.7 mmol/L)|$145 ($3.7 mmol/L)|\u001b[0m\u001b[3;34m                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mValues given are in mg/dL. To convert to SI units, divide the results for TC, LDL-C, HDL-C, and non–HDL-C by \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m38.6; for triglycerides, divide by 88.6.\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m*Values for plasma lipid and lipoprotein levels are from the NCEP Expert Panel on Cholesterol Levels in \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mChildren. Non–HDL-C values from the Bogalusa Heart Study are equivalent to the NCEP Pediatric Panel cutpoints \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfor LDL-C.\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m†The cutpoints for high and borderline high represent approximately the 95th and 75th percentiles, \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrespectively. Low cutpoints for HDL-C represent approximately the 10th percentile.\u001b[0m\u001b[3;34m                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; NCEP, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNational Cholesterol Education Program; SI, Système international d’unités (International System of Units); and\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTC, total cholesterol.\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHypercholesterolemia show reasonable LDL-C lowering with no significant adverse effects (S4.4.4.3-13). \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNonsystemic bile acid sequestrants can be useful for LDL-C lowering, but tolerability is an issue \u001b[0m\u001b[3;34m             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-13—S4.4.4.3-16).\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. Lipid testing during childhood can identify the severe hypercholesterolemia phenotype (S4.4.4.3-35). Severe \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia, which includes FH, can be identified in children and adolescents with an LDL-C level $190\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg/dL ($4.9 mmol/L). Moreover, children and adolescents with LDL-C $160 mg/dL ($4.1 mmol/L) and a family \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhistory of early atherosclerosis or similarly elevated cholesterol in 1 parent likely are those with FH and \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mrelated genetic disorders associated with accelerated ASCVD (S4.4.4.3-17—S4.4.4.3-21).\u001b[0m\u001b[3;34m                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mSubclinical atherosclerosis data suggest divergence between affected and unaffected children and adolescents \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeginning at age 10 years (S4.4.4.3-28), which supports screening by this age, although this topic is still \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsidered controversial (S4.4.4.3-36). Screening is advised beginning at age 2 years if a family history is \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msuggestive of either early CVD or significant primary hypercholesterolemia. Identification of a child with \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34msevere hypercholesterolemia should prompt screening of extended family members (e.g., reverse-cascade \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mscreening), according to studies outside the United States demonstrating efficacy of this approach \u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(S4.4.4.3-37). Screening for severe\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e300 Grundy et al.\u001b[0m\u001b[3;34m                                                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E 2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C is inadequately controlled with drug therapy, LDL apheresis is an option. Referral to a lipid specialist \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmay be indicated.\u001b[0m\u001b[3;34m                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. Patients with primary severe hypercholesterolemia (LDL-C levels ≥190 mg/dL [≥4.9 mmol/L]) have a high-risk \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof ASCVD (S4.2-2, S4.2-4, S4.2-18) and premature and recurrent coronary events (S4.2-3). Although there have \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mbeen no randomized, placebo-controlled trials of statin therapy done exclusively in subjects with LDL-C levels \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m≥190 mg/dL (≥4.9 mmol/L), a placebo-controlled primary prevention study performed in men with a mean baseline \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C level of 192.17 mg/dL (4.90.4 mmol/L) demonstrated a reduced incidence of MI and cardiovascular death in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthose receiving pravastatin 40 mg daily (S4.2-5). These findings were extended in a post hoc analysis of 2,560 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mexclusively primary-prevention subjects in that RCT and in a 20-year observational post-trial long-term \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mfollow-up study (S4.2-19). In addition, retrospective cohort studies have demonstrated that statin therapy \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduces risk of incident MI (S4.2-6) and of CHD and all-cause death (S4.2-1) in patients with phenotypic or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgenetically confirmed FH. Because moderate- or high-intensity statins have been shown to reduce ASCVD risk in \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mboth primary- and secondary-prevention trials and because high-intensity statins provide greater ASCVD risk \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction than moderate-intensity statins or placebo (S4.2-7), maximally tolerated statin therapy should be \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34madministered to patients with primary severe hypercholesterolemia.\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2. A large placebo-controlled RCT examined the effect of simvastatin 80 mg daily, with or without ezetimibe 10 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmg daily, on carotid intima-media thickness and plasma lipoproteins over 2 years. Mean LDL-C reduction was \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mgreater in the combined-therapy group, but there was no difference in carotid intima-media thickness between \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthe 2 groups. The study was not powered to examine the risk of ASCVD events (S4.2-10). However, a very large \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mplacebo-controlled RCT examining ASCVD outcomes in post-ACS patients, performed over a period of 7 years, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mshowed that the addition of ezetimibe 10 mg to simvastatin 40 mg daily resulted in greater ASCVD risk reduction\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mthan that produced by statin monotherapy (S4.2-8). Secondary-prevention patients with certain ASCVD risk \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mindicators exhibit greater ASCVD risk reduction from ezetimibe therapy than do patients without these \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcharacteristics (S4.2-20). Patients with severe hypercholesterolemia who are adherent to statins, achieve <50% \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mreduction in LDL-C levels with maximally tolerated statin therapy, and have an LDL-C level ≥100 mg/dL (≥2.6 \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmmol/L) are likely to derive additional ASCVD risk reduction from ezetimibe add-on therapy through additional \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mLDL-C lowering (S4.2-9).\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m3. When administered to patients with severe hypercholesterolemia who are taking maximally tolerated statins \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mwith or without ezetimibe, bile acid sequestrants have demonstrated LDL-C-lowering efficacy (S4.2-11, S4.2-12).\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mHowever, the clinical utility of bile acid sequestrants is limited by the absence of ASCVD outcomes data when \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mused in combination with statins, as well as by the issues of twice-daily dosing, high pill burden, the absence\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof well-tolerated generic formulations, drug interactions, and the potential for triglyceride elevation. \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mNonetheless, in patients with very severe hypercholesterolemia, adding sequestrants to otherwise maximal \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcholesterol-lowering therapy in patients who are not eligible for a PCSK9 inhibitor may be considered.\u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m4. PCSK9 inhibitors are promising drugs for treatment of FH\u001b[0m\u001b[3;34m                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprevention of cardiovascular disease: an opportunity to harmonize guidelines. JAMA Cardiol. 2017;2:1175–6.\u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.2-10. Berry JD, Dyer A, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012; \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m366:321–9.\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.2-11. Lehr AL, Driver SL, Stone NJ. The ABCDs of lifestyle counseling. JAMA Cardiol. 2016;1:505–6.\u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.2-12. Omura JD, Watson KB, Loustalot F, et al. Primary care providers’ awareness of physical \u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mactivity-related intensive behavioral counseling services for cardiovascular disease prevention. Am J Health \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mPromot. 2018. 890117118784226.\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.4.4.3. Children and Adolescents\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-1. Iannuzzi A, Licenziati MR, Vacca M, et al. Comparison of two diets of varying glycemic index on \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcarotid subclinical atherosclerosis in obese children. Heart Vessels. 2009;24:419–24.\u001b[0m\u001b[3;34m                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-2. Murphy EC, Carson L, Neal W, et al. Effects of an exercise intervention using Dance Dance \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mRevolution on endothelial function and other risk factors in overweight children. Int J Pediatr Obes. \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2009;4:205–14.\u001b[0m\u001b[3;34m                                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-3. Pratt RE, Kavey RE, Quinzi D. Combined dyslipidemia in obese children: response to a focused \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mlifestyle approach. J Clin Lipidol. 2014;8:181–6.\u001b[0m\u001b[3;34m                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-4. de Ferranti SD, Milliren CE, Denhoff ER, et al. Providing food to treat adolescents at risk for \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcardiovascular disease. Obesity (Silver Spring). 2015; 23:2109–17.\u001b[0m\u001b[3;34m                                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-5. Niinikoski H, Lagstrom H, Jokinen E, et al. Impact of repeated dietary counseling between infancy \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study. Circulation. 2007; \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m116:1032–40.\u001b[0m\u001b[3;34m                                                                                                   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-6. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdiet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary \u001b[0m\u001b[3;34m         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mIntervention Study in Children (DISC). Pediatrics. 2001;107:256–64.\u001b[0m\u001b[3;34m                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-7. Dorgan JF, Liu L, Barton BA, et al. Adolescent diet and metabolic syndrome in young women: results \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mof the Dietary Intervention Study in Children (DISC) follow-up study. J Clin Endocrinol Metab. \u001b[0m\u001b[3;34m                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m2011;96:E1999–2008.\u001b[0m\u001b[3;34m                                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-8. Wong H, Chahal N, Manlhiot C, et al. Flaxseed in pediatric hyperlipidemia: a placebo-controlled, \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mblinded, randomized clinical trial of dietary flaxseed supplementation for children and adolescents with \u001b[0m\u001b[3;34m      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemia. JAMA Pediatr. 2013;167:708–13.\u001b[0m\u001b[3;34m                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-9. Zachariah JP, Chan J, Mendelson MM, et al. Adolescent dyslipidemia and standardized lifestyle \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mmodification: benchmarking real-world practice. J Am Coll Cardiol. 2016;68:2122–3.\u001b[0m\u001b[3;34m                             \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-10. Torvik K, Narverud I, Ottestad I, et al. Dietary counseling is associated with an improved lipid \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mprofile in children with familial hypercholesterolemia. Atherosclerosis. 2016;252:21–7.\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-11. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mPaediatr. 1992;81:682–5.\u001b[0m\u001b[3;34m                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.4.4.3-12. Tershakovec AM, Shannon BM, Achterberg CL, et al. One-year follow-up of nutrition education for \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypercholesterolemic children.\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# e318\u001b[0m\u001b[3;34m                                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Grundy et al.\u001b[0m\u001b[3;34m                                                                                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J A C C V O L . 7 3 , N O . 2 4 , 2 0 1 9\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 2018 Cholesterol Clinical Practice Guideline\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# J U N E  2 5 , 2 0 1 9 : e 2 8 5 - 3 5 0\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 4.5.2. Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendations for Hypertriglyceridemia\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mReferenced studies that support recommendations are summarized in Online Data Supplements 31 and 32.\u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|COR|LOE|RECOMMENDATIONS|\u001b[0m\u001b[3;34m                                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|---|---|---|\u001b[0m\u001b[3;34m                                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|I|B-NR|In adults 20 years of age or older with moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175 to 499 mg/dL [2.0 to 5.6 mmol/L]), clinicians should address and treat lifestyle factors \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m(obesity and metabolic syndrome), secondary factors (diabetes mellitus, chronic liver or kidney disease and/or \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mnephrotic syndrome, hypothyroidism), and medications that increase triglycerides (S4.5.2-1).|\u001b[0m\u001b[3;34m                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with moderate or severe hypertriglyceridemia and ASCVD risk of 7.5% or\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhigher, it is reasonable to reevaluate ASCVD risk after lifestyle and secondary factors are addressed and to \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsider a persistently elevated triglyceride level as a factor favoring initiation or intensification of \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mstatin therapy (see Section 4.4.2.) (S4.5.2-2—S4.5.2-6).|\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-R|In adults 40 to 75 years of age with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]) and ASCVD risk of 7.5% or higher, it is reasonable to address reversible causes of high \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglyceride and to initiate statin therapy (S4.5.2-3—S4.5.2-5, S4.5.2-7, S4.5.2-8).|\u001b[0m\u001b[3;34m                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m|IIa|B-NR|In adults with severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL [≥5.7 mmol/L]), and \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mespecially fasting triglycerides ≥1,000 mg/dL (11.3 mmol/L)), it is reasonable to identify and address other \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mcauses of hypertriglyceridemia, and if triglycerides are persistently elevated or increasing, to further reduce\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides by implementation of a very low-fat diet, avoidance of refined carbohydrates and alcohol, \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mconsumption of omega-3 fatty acids, and, if necessary to prevent acute pancreatitis, fibrate therapy (S4.5.2-7,\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mS4.5.2-9).|\u001b[0m\u001b[3;34m                                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Synopsis\u001b[0m\u001b[3;34m                                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mTwo categories of hypertriglyceridemia consist of moderate hypertriglyceridemia (fasting or nonfasting \u001b[0m\u001b[3;34m        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtriglycerides 175-499 mg/dL [2.0-5.6 mmol/L]) and severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[≥5.6 mmol/L]). In the former, excess triglycerides are carried in VLDL. In the latter, most patients have \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL plus chylomicrons. VLDL are believed to be atherogenic, similar to LDL. There are many causes of \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34melevated VLDL, and it is reasonable to reduce their levels to reduce risk of ASCVD. With severe \u001b[0m\u001b[3;34m               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mhypertriglyceridemia, elevations of VLDL raise risk of ASCVD, but increases in chylomicrons impart risk of \u001b[0m\u001b[3;34m    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34macute pancreatitis. Therapies should address excesses in both lipoproteins.\u001b[0m\u001b[3;34m                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Recommendation-Specific Supportive Text\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m1. In patients with moderate hypertriglyceridemia, it is reasonable to reduce both atherogenic VLDL and \u001b[0m\u001b[3;34m       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34massociated risk factors by nonpharmacological means where possible. This can best be achieved by identification\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mand treatment of the multiple underlying causes of elevated triglycerides (e.g., lifestyle causes, secondary \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mdisorders, and triglyceride-raising drugs) (S4.5.2-1). Triglyceride-raising drugs include oral estrogens, \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mtamoxifen, raloxifene, retinoids,\u001b[0m\u001b[3;34m                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# Brottet et al.\u001b[0m\u001b[3;34m                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# JACC Vol. 57, No. 8, 2011\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# ECVD Guideline: Full Text\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# February 22, 2011:e16 –94\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.2. Cessation of Tobacco Smoking\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.2.1. Recommendation for Cessation of Tobacco Smoking\u001b[0m\u001b[3;34m                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3. Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.3.1. Recommendations for Control of Hyperlipidemia\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.4. Management of Diabetes Mellitus\u001b[0m\u001b[3;34m                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.4.1. Recommendations for Management of Diabetes Mellitus in Patients With Atherosclerosis of the \u001b[0m\u001b[3;34m          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mExtracranial Carotid or Vertebral Arteries\u001b[0m\u001b[3;34m                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.5. Hyperhomocysteinemia\u001b[0m\u001b[3;34m                                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.6. Obesity and the Metabolic Syndrome\u001b[0m\u001b[3;34m                                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.7. Physical Inactivity\u001b[0m\u001b[3;34m                                                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8. Antithrombotic Therapy\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8.1. Recommendations for Antithrombotic Therapy in Patients With Extracranial Carotid Atherosclerotic \u001b[0m\u001b[3;34m     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mDisease Not Undergoing Revascularization\u001b[0m\u001b[3;34m                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 6.8.2. Nonsteroidal Anti-Inflammatory Drugs\u001b[0m\u001b[3;34m                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7. Revascularization\u001b[0m\u001b[3;34m                                                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.1. Recommendations for Selection of Patients for Carotid Revascularization\u001b[0m\u001b[3;34m                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2. Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1. Randomized Trials of Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1.1. CAROTID ENDARTERECTOMY IN SYMPTOMATIC PATIENTS\u001b[0m\u001b[3;34m                                                      \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.1.2. CAROTID ENDARTERECTOMY IN ASYMPTOMATIC PATIENTS\u001b[0m\u001b[3;34m                                                     \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2. Factors Affecting the Outcome of Carotid Endarterectomy\u001b[0m\u001b[3;34m                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.1. TECHNICAL CONSIDERATIONS\u001b[0m\u001b[3;34m                                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.2. CASE SELECTION AND OPERATOR EXPERIENCE\u001b[0m\u001b[3;34m                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.2.3. DEMOGRAPHIC AND CLINICAL FACTORS\u001b[0m\u001b[3;34m                                                                    \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.3. Risks Associated With Carotid Endarterectomy\u001b[0m\u001b[3;34m                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.4. Carotid Endarterectomy in Patients With Unfavorable Anatomy\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.5. Evolution in the Safety of Carotid Surgery\u001b[0m\u001b[3;34m                                                            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.6. Evolution of Medical Therapy\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.2.7. Recommendations for Periprocedural Management of Patients Undergoing Carotid Endarterectomy\u001b[0m\u001b[3;34m           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3. Carotid Artery Stenting\u001b[0m\u001b[3;34m                                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.1. Multicenter Registry Studies\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2. Risks Associated With Carotid Artery Stenting\u001b[0m\u001b[3;34m                                                         \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2.1. CARDIOVASCULAR COMPLICATIONS\u001b[0m\u001b[3;34m                                                                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.2.2. NEUROLOGICAL COMPLICATIONS\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.3. Prevention of Cerebral Embolism in Patients Undergoing Catheter-Based Carotid Intervention\u001b[0m\u001b[3;34m            \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.4. Intravascular Ultrasound Imaging in Conjunction With Catheter-Based Carotid Intervention\u001b[0m\u001b[3;34m              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.3.5. Management of Patients Undergoing Endovascular Carotid Artery Stenting\u001b[0m\u001b[3;34m                                \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4. Comparative Assessment of Carotid Endarterectomy and Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.1. Nonrandomized Comparison of Carotid Endarterectomy With Carotid Artery Stenting\u001b[0m\u001b[3;34m                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.2. Meta-Analyses Comparing Carotid Endarterectomy and Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3. Randomized Trials Comparing Carotid Endarterectomy and Carotid Artery Stenting\u001b[0m\u001b[3;34m                        \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3.1. HIGH-RISK PATIENTS\u001b[0m\u001b[3;34m                                                                                  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.3.2. CONVENTIONAL-RISK PATIENTS\u001b[0m\u001b[3;34m                                                                          \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.4.4. Selection of Carotid Endarterectomy or Carotid Artery Stenting for Individual Patients With Carotid \u001b[0m\u001b[3;34m  \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStenosis\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5. Durability of Carotid Revascularization\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5.1. Recommendations for Management of Patients Experiencing Restenosis After Carotid Endarterectomy or \u001b[0m\u001b[3;34m   \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34mStenting\u001b[0m\u001b[3;34m                                                                                                       \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m# 7.5.2. Clinical Durability of Carotid Surgery and Carotid Stenting\u001b[0m\u001b[3;34m                                           \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m                                                                                                               \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m#\u001b[0m\u001b[3;34m                                                                                                              \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭────────────────────────────────────────────────</span> Tool Call Info <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">─────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Tool called: search_bing_grounding                                                              │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m───────────────────────────────────────────────\u001b[0m Tool Call Info \u001b[1;35m────────────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Tool called: search_bing_grounding\u001b[0m\u001b[1;35m                                                             \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080\">╭───────────────────────────────────────────────</span> Arguments String <span style=\"color: #800080; text-decoration-color: #800080\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">│ [DEBUG] Step 1: arguments_str: {\"query\": \"FDA new hyperlipidemia medications February 2025\"}                    │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[35m╭─\u001b[0m\u001b[35m──────────────────────────────────────────────\u001b[0m Arguments String \u001b[35m───────────────────────────────────────────────\u001b[0m\u001b[35m─╮\u001b[0m\n",
       "\u001b[35m│\u001b[0m\u001b[35m \u001b[0m\u001b[35m[DEBUG] Step 1: arguments_str: {\"query\": \"FDA new hyperlipidemia medications February 2025\"}\u001b[0m\u001b[35m                   \u001b[0m\u001b[35m \u001b[0m\u001b[35m│\u001b[0m\n",
       "\u001b[35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008000; text-decoration-color: #008000\">╭───────────────────────────────────────────────</span> Parsed Arguments <span style=\"color: #008000; text-decoration-color: #008000\">────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">│ [DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA new hyperlipidemia medications February 2025'}      │</span>\n",
       "<span style=\"color: #008000; text-decoration-color: #008000\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[32m╭─\u001b[0m\u001b[32m──────────────────────────────────────────────\u001b[0m Parsed Arguments \u001b[32m───────────────────────────────────────────────\u001b[0m\u001b[32m─╮\u001b[0m\n",
       "\u001b[32m│\u001b[0m\u001b[32m \u001b[0m\u001b[32m[DEBUG] Step 1: function_args (JSON parsed): {'query': 'FDA new hyperlipidemia medications February 2025'}\u001b[0m\u001b[32m     \u001b[0m\u001b[32m \u001b[0m\u001b[32m│\u001b[0m\n",
       "\u001b[32m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╭───────────────────────────────────────────────────</span> Tool Call <span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Step 1**: LLM calls tool search_bing_grounding                                                                │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│                                                                                                                 │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ **Arguments**:                                                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ {                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│   \"query\": \"FDA new hyperlipidemia medications February 2025\"                                                   │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">│ }                                                                                                               │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;34m╭─\u001b[0m\u001b[1;34m──────────────────────────────────────────────────\u001b[0m Tool Call \u001b[1;34m──────────────────────────────────────────────────\u001b[0m\u001b[1;34m─╮\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Step 1**: LLM calls tool \u001b[0m\u001b[1;34msearch_bing_grounding\u001b[0m\u001b[1;34m                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m                                                                                                               \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m**Arguments**:\u001b[0m\u001b[1;34m                                                                                                 \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m{\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m  \"query\": \"FDA new hyperlipidemia medications February 2025\"\u001b[0m\u001b[1;34m                                                  \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m│\u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m}\u001b[0m\u001b[1;34m                                                                                                              \u001b[0m\u001b[1;34m \u001b[0m\u001b[1;34m│\u001b[0m\n",
       "\u001b[1;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭───────────────────────────────────────────</span> Tool Implementation Call <span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ [DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'FDA new hyperlipidemia │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ medications February 2025'}                                                                                     │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─\u001b[0m\u001b[1;35m──────────────────────────────────────────\u001b[0m Tool Implementation Call \u001b[1;35m───────────────────────────────────────────\u001b[0m\u001b[1;35m─╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m[DEBUG] Step 1: Calling tool implementation: search_bing_grounding with args: {'query': 'FDA new hyperlipidemia\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mmedications February 2025'}\u001b[0m\u001b[1;35m                                                                                    \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Tool Invoked: Bing Grounding Search                                                                             │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">│ Query: FDA new hyperlipidemia medications February 2025                                                         │</span>\n",
       "<span style=\"color: #800080; text-decoration-color: #800080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;35m╭─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╮\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mTool Invoked: Bing Grounding Search\u001b[0m\u001b[1;35m                                                                            \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m│\u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35mQuery: FDA new hyperlipidemia medications February 2025\u001b[0m\u001b[1;35m                                                        \u001b[0m\u001b[1;35m \u001b[0m\u001b[1;35m│\u001b[0m\n",
       "\u001b[1;35m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╭──────────────────────────────────────────────────</span> Tool Output <span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">│ [DEBUG] Step 1: Tool output: No results found.                                                                  │</span>\n",
       "<span style=\"color: #000080; text-decoration-color: #000080; font-style: italic\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[3;34m╭─\u001b[0m\u001b[3;34m─────────────────────────────────────────────────\u001b[0m Tool Output \u001b[3;34m─────────────────────────────────────────────────\u001b[0m\u001b[3;34m─╮\u001b[0m\n",
       "\u001b[3;34m│\u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m[DEBUG] Step 1: Tool output: No results found.\u001b[0m\u001b[3;34m                                                                 \u001b[0m\u001b[3;34m \u001b[0m\u001b[3;34m│\u001b[0m\n",
       "\u001b[3;34m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╭──────────────────────────────────────────────────</span> Step Start <span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">───────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">│ **Step 2**: Starting step 2                                                                                     │</span>\n",
       "<span style=\"color: #008080; text-decoration-color: #008080; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;36m╭─\u001b[0m\u001b[1;36m─────────────────────────────────────────────────\u001b[0m Step Start \u001b[1;36m──────────────────────────────────────────────────\u001b[0m\u001b[1;36m─╮\u001b[0m\n",
       "\u001b[1;36m│\u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m**Step 2**: Starting step 2\u001b[0m\u001b[1;36m                                                                                    \u001b[0m\u001b[1;36m \u001b[0m\u001b[1;36m│\u001b[0m\n",
       "\u001b[1;36m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╭─────────────────────────────────────────────────</span> Raw Response <span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ [DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='Here is a summary of the findings          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ regarding your patient, Gloria Paul, a 79-year-old with hyperlipidemia:\\n\\n### Patient Details\\n- **Name**:     │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Gloria Paul\\n- **Date of Birth**: July 15, 1944 (Age: 79)\\n- **Contact**: 428-674-1336, keymary@example.com\\n-  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Address**: 62908 Fuentes Cove, Lewisberg, MN, 13491, India\\n- **Medical Condition**: Hyperlipidemia\\n-        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Medications**: Atorvastatin\\n- **Allergies**: None\\n- **Blood Type**: O+\\n- **Last Visit Date**: March 26,    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ 2024\\n- **Smoking Status**: Never Smoker\\n- **Alcohol Consumption**: Light drinker (1-2 times a week)\\n-        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Occupation**: Administrator\\n- **Height**: 176.2 cm\\n- **Weight**: 77.7 kg\\n- **Blood Pressure**: 120/79      │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ mmHg\\n- **Heart Rate**: 90 bpm\\n- **Temperature**: 37.6 °C\\n\\n### ACC Guidelines for Hyperlipidemia\\n1.         │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ **Statin Use**: \\n   - Statin treatment is recommended for all patients with extracranial carotid or vertebral  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ atherosclerosis to reduce LDL cholesterol below 100 mg/dL (Level of Evidence: B).\\n   - It is reasonable for    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ patients to aim for LDL cholesterol levels near or below 70 mg/dL after an ischemic stroke (Level of Evidence:  │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ B).\\n2. **Alternative Therapies**:\\n   - If statins fail to achieve targeted LDL levels, adding other           │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medications, such as bile acid sequestrants or niacin, is effective (Level of Evidence: B).\\n   - Non-statin    │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ alternatives are reasonable for patients intolerant to statins.\\n\\n### FDA Updates\\nUnfortunately, the search   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ for recent information on new hyperlipidemia medications from the FDA as of February 2025 yielded no results.   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ It seems that either no new medications have been approved, or the data is currently unavailable.\\n\\n###        │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ Conclusion\\nGloria is appropriately managed on Atorvastatin, aligning with ACC guidelines. Monitoring her LDL   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ levels is essential, and considering further steps if targets are not reached may be necessary. No new          │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ medications are specifically noted from the FDA for hyperlipidemia, so current therapy should continue unless   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ new evidence arises.\\n\\nIf you need more specific guidance or updates on additional treatment options for her   │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">│ condition, feel free to ask!', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None) │</span>\n",
       "<span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[2m╭─\u001b[0m\u001b[2m────────────────────────────────────────────────\u001b[0m Raw Response \u001b[2m─────────────────────────────────────────────────\u001b[0m\u001b[2m─╮\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m[DEBUG] Step 2: Raw response_message: ChatCompletionMessage(content='Here is a summary of the findings \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mregarding your patient, Gloria Paul, a 79-year-old with hyperlipidemia:\\n\\n### Patient Details\\n- **Name**: \u001b[0m\u001b[2m   \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mGloria Paul\\n- **Date of Birth**: July 15, 1944 (Age: 79)\\n- **Contact**: 428-674-1336, keymary@example.com\\n- \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Address**: 62908 Fuentes Cove, Lewisberg, MN, 13491, India\\n- **Medical Condition**: Hyperlipidemia\\n- \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Medications**: Atorvastatin\\n- **Allergies**: None\\n- **Blood Type**: O+\\n- **Last Visit Date**: March 26, \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m2024\\n- **Smoking Status**: Never Smoker\\n- **Alcohol Consumption**: Light drinker (1-2 times a week)\\n- \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Occupation**: Administrator\\n- **Height**: 176.2 cm\\n- **Weight**: 77.7 kg\\n- **Blood Pressure**: 120/79 \u001b[0m\u001b[2m    \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmmHg\\n- **Heart Rate**: 90 bpm\\n- **Temperature**: 37.6 °C\\n\\n### ACC Guidelines for Hyperlipidemia\\n1. \u001b[0m\u001b[2m       \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2m**Statin Use**: \\n   - Statin treatment is recommended for all patients with extracranial carotid or vertebral \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2matherosclerosis to reduce LDL cholesterol below 100 mg/dL (Level of Evidence: B).\\n   - It is reasonable for \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mpatients to aim for LDL cholesterol levels near or below 70 mg/dL after an ischemic stroke (Level of Evidence: \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mB).\\n2. **Alternative Therapies**:\\n   - If statins fail to achieve targeted LDL levels, adding other \u001b[0m\u001b[2m         \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedications, such as bile acid sequestrants or niacin, is effective (Level of Evidence: B).\\n   - Non-statin \u001b[0m\u001b[2m  \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2malternatives are reasonable for patients intolerant to statins.\\n\\n### FDA Updates\\nUnfortunately, the search \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mfor recent information on new hyperlipidemia medications from the FDA as of February 2025 yielded no results. \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mIt seems that either no new medications have been approved, or the data is currently unavailable.\\n\\n### \u001b[0m\u001b[2m      \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mConclusion\\nGloria is appropriately managed on Atorvastatin, aligning with ACC guidelines. Monitoring her LDL \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mlevels is essential, and considering further steps if targets are not reached may be necessary. No new \u001b[0m\u001b[2m        \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mmedications are specifically noted from the FDA for hyperlipidemia, so current therapy should continue unless \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mnew evidence arises.\\n\\nIf you need more specific guidance or updates on additional treatment options for her \u001b[0m\u001b[2m \u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m│\u001b[0m\u001b[2m \u001b[0m\u001b[2mcondition, feel free to ask!', refusal=None, role='assistant', audio=None, function_call=None, tool_calls=None)\u001b[0m\u001b[2m \u001b[0m\u001b[2m│\u001b[0m\n",
       "\u001b[2m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    },
    {
     "data": {
      "text/html": [
       "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╭─────────────────────────────────────────────────</span><span style=\"color: #808000; text-decoration-color: #808000\"> Final Answer </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">──────────────────────────────────────────────────╮</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Here is a summary of the findings regarding your patient, Gloria Paul, a 79-year-old with hyperlipidemia:       </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Patient Details                                                                                             </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Name**: Gloria Paul                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Date of Birth**: July 15, 1944 (Age: 79)                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Contact**: 428-674-1336, keymary@example.com                                                                </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Address**: 62908 Fuentes Cove, Lewisberg, MN, 13491, India                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medical Condition**: Hyperlipidemia                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Medications**: Atorvastatin                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Allergies**: None                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Type**: O+                                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Last Visit Date**: March 26, 2024                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Smoking Status**: Never Smoker                                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Alcohol Consumption**: Light drinker (1-2 times a week)                                                     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Occupation**: Administrator                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Height**: 176.2 cm                                                                                          </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Weight**: 77.7 kg                                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Blood Pressure**: 120/79 mmHg                                                                               </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Heart Rate**: 90 bpm                                                                                        </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> - **Temperature**: 37.6 °C                                                                                      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### ACC Guidelines for Hyperlipidemia                                                                           </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 1. **Statin Use**:                                                                                              </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - Statin treatment is recommended for all patients with extracranial carotid or vertebral atherosclerosis to </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> reduce LDL cholesterol below 100 mg/dL (Level of Evidence: B).                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - It is reasonable for patients to aim for LDL cholesterol levels near or below 70 mg/dL after an ischemic   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> stroke (Level of Evidence: B).                                                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2. **Alternative Therapies**:                                                                                   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - If statins fail to achieve targeted LDL levels, adding other medications, such as bile acid sequestrants   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> or niacin, is effective (Level of Evidence: B).                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">    - Non-statin alternatives are reasonable for patients intolerant to statins.                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### FDA Updates                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Unfortunately, the search for recent information on new hyperlipidemia medications from the FDA as of February  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> 2025 yielded no results. It seems that either no new medications have been approved, or the data is currently   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> unavailable.                                                                                                    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ### Conclusion                                                                                                  </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> Gloria is appropriately managed on Atorvastatin, aligning with ACC guidelines. Monitoring her LDL levels is     </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> essential, and considering further steps if targets are not reached may be necessary. No new medications are    </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> specifically noted from the FDA for hyperlipidemia, so current therapy should continue unless new evidence      </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> arises.                                                                                                         </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\">                                                                                                                 </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> If you need more specific guidance or updates on additional treatment options for her condition, feel free to   </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span><span style=\"color: #008000; text-decoration-color: #008000; font-weight: bold\"> ask!                                                                                                            </span><span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">│</span>\n",
       "<span style=\"color: #808000; text-decoration-color: #808000; font-weight: bold\">╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯</span>\n",
       "</pre>\n"
      ],
      "text/plain": [
       "\u001b[1;33m╭─\u001b[0m\u001b[1;33m────────────────────────────────────────────────\u001b[0m\u001b[33m Final Answer \u001b[0m\u001b[1;33m─────────────────────────────────────────────────\u001b[0m\u001b[1;33m─╮\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mHere is a summary of the findings regarding your patient, Gloria Paul, a 79-year-old with hyperlipidemia:\u001b[0m\u001b[1;32m      \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Patient Details\u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Name**: Gloria Paul\u001b[0m\u001b[1;32m                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Date of Birth**: July 15, 1944 (Age: 79)\u001b[0m\u001b[1;32m                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Contact**: 428-674-1336, keymary@example.com\u001b[0m\u001b[1;32m                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Address**: 62908 Fuentes Cove, Lewisberg, MN, 13491, India\u001b[0m\u001b[1;32m                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medical Condition**: Hyperlipidemia\u001b[0m\u001b[1;32m                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Medications**: Atorvastatin\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Allergies**: None\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Type**: O+\u001b[0m\u001b[1;32m                                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Last Visit Date**: March 26, 2024\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Smoking Status**: Never Smoker\u001b[0m\u001b[1;32m                                                                             \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Alcohol Consumption**: Light drinker (1-2 times a week)\u001b[0m\u001b[1;32m                                                    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Occupation**: Administrator\u001b[0m\u001b[1;32m                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Height**: 176.2 cm\u001b[0m\u001b[1;32m                                                                                         \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Weight**: 77.7 kg\u001b[0m\u001b[1;32m                                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Blood Pressure**: 120/79 mmHg\u001b[0m\u001b[1;32m                                                                              \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Heart Rate**: 90 bpm\u001b[0m\u001b[1;32m                                                                                       \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m- **Temperature**: 37.6 °C\u001b[0m\u001b[1;32m                                                                                     \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### ACC Guidelines for Hyperlipidemia\u001b[0m\u001b[1;32m                                                                          \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m1. **Statin Use**: \u001b[0m\u001b[1;32m                                                                                            \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - Statin treatment is recommended for all patients with extracranial carotid or vertebral atherosclerosis to\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mreduce LDL cholesterol below 100 mg/dL (Level of Evidence: B).\u001b[0m\u001b[1;32m                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - It is reasonable for patients to aim for LDL cholesterol levels near or below 70 mg/dL after an ischemic \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mstroke (Level of Evidence: B).\u001b[0m\u001b[1;32m                                                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2. **Alternative Therapies**:\u001b[0m\u001b[1;32m                                                                                  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - If statins fail to achieve targeted LDL levels, adding other medications, such as bile acid sequestrants \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mor niacin, is effective (Level of Evidence: B).\u001b[0m\u001b[1;32m                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m   - Non-statin alternatives are reasonable for patients intolerant to statins.\u001b[0m\u001b[1;32m                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### FDA Updates\u001b[0m\u001b[1;32m                                                                                                \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mUnfortunately, the search for recent information on new hyperlipidemia medications from the FDA as of February \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m2025 yielded no results. It seems that either no new medications have been approved, or the data is currently \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32munavailable.\u001b[0m\u001b[1;32m                                                                                                   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m### Conclusion\u001b[0m\u001b[1;32m                                                                                                 \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mGloria is appropriately managed on Atorvastatin, aligning with ACC guidelines. Monitoring her LDL levels is \u001b[0m\u001b[1;32m   \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32messential, and considering further steps if targets are not reached may be necessary. No new medications are \u001b[0m\u001b[1;32m  \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mspecifically noted from the FDA for hyperlipidemia, so current therapy should continue unless new evidence \u001b[0m\u001b[1;32m    \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32marises.\u001b[0m\u001b[1;32m                                                                                                        \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m                                                                                                               \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mIf you need more specific guidance or updates on additional treatment options for her condition, feel free to \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m│\u001b[0m\u001b[1;32m \u001b[0m\u001b[1;32mask!\u001b[0m\u001b[1;32m                                                                                                           \u001b[0m\u001b[1;32m \u001b[0m\u001b[1;33m│\u001b[0m\n",
       "\u001b[1;33m╰─────────────────────────────────────────────────────────────────────────────────────────────────────────────────╯\u001b[0m\n"
      ]
     },
     "metadata": {},
     "output_type": "display_data"
    }
   ],
   "source": [
    "run_multi_step_agent(\"I have a 79-year-old patient named Gloria Paul with hyperlipidemia. She's on Atorvastatin. Can you confirm her medical details from the database, check the ACC guidelines for hyperlipidemia, and see if there are any new medication updates from the FDA as of Feb 2025? Then give me a summary.\")"
   ]
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": ".venv",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.13.2"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
